Melanoma is a highly aggressive cancer, accounting for up to 75% of skin cancer deaths. A small proportion of melanoma cases can be ascribed to the presence of highly penetrant germline mutations, and approximately 40% of hereditary melanoma cases are caused by CDKN2A mutations. The current study sought to investigate whether the presence of germline CDKN2A mutations or the occurrence of cutaneous melanoma would result in constitutive genome-wide DNA methylation changes. The leukocyte methylomes of two groups of melanoma patients (those with germline CDKN2A mutations and those without CDKN2A mutations) were analyzed together with the profile of a control group of individuals. A pattern of DNA hypomethylation was detected in the CDKN2A-negative patients relative to both CDKN2A-mutated patients and controls. Additionally, we delineated a panel of 90 CpG sites that were differentially methylated in CDKN2A-mutated patients relative to controls. Although we identified a possible constitutive epigenetic signature in CDKN2A-mutated patients, the occurrence of reported SNPs at the detected CpG sites complicated the data interpretation. Thus, further studies are required to elucidate the impact of these findings on melanoma predisposition and their possible effect on the penetrance of CDKN2A mutations.
Melanoma is a rare but highly aggressive cancer, accounting for 75% of skin cancer deaths (Schinke et al., 2010) . The majority of melanoma cases is sporadic, but approximately 10% are hereditary and arise from highly penetrant germline mutations (Ward et al., 2012) . The full genetic architecture underlying melanoma risk has not yet been elucidated, but CDKN2A is well established as a high-risk susceptibility gene, also known to increase the risk of pancreatic cancer (Udayakumar et al., 2010) . CDKN2A encodes two different tumor suppressor proteins (p16 INK4a and p14 ARF ), but the majority of the mutations affect p16 INK4a , accounting for approximately 40% of familial cases, most of which present with multiple melanomas. A few families were also reported to segregate germline mutations in either the p14 ARF isoform of CDKN2A or the CDK4 gene (Puntervoll et al., 2013; Tsao et al., 2012) . The penetrance of CDKN2A mutations is incomplete, depending on age and geographic location; in addition, different clinical features have been reported in patients from the same family (Hyland et al., 2013) . These observations indicate that additional genetic and environmental factors are relevant to cancer development and progression in individuals carrying CDKN2A mutations. Epigenetic modifications can be defined as changes in chromatin that do not modify the underlying DNA sequence; these modifications are stable and heritable yet reversible (Bonasio et al., 2010) . Epigenetic patterns serve as markers of gene activity as well as chromatin state (Srivastava et al., 2010) . One major epigenetic process is DNA methylation, a chemical modification occurring mostly in CpG dinucleotides (Goll and Bestor, 2005) . DNA methylation is an epigenetic mark controlling several biological processes, ranging from physiological conditions Experimental and Molecular Pathology 97 (2014) [425] [426] [427] [428] [429] [430] [431] [432] to responses to diseases such as cancer, in which aberrant profiles have been extensively documented (Hesson et al., 2010; Sharma et al., 2010) . Epigenetic inactivation of CDKN2A is a common finding in melanomas (Freedberg et al., 2008) , and aberrant methylation has also been reported for other genes (Schinke et al., 2010) , with only a few of them exhibiting hypomethylation (Loriot et al., 2006) .
It has been proposed that genetic mutations can lead to DNA methylation changes (Richards, 2006) . The effects of mutations reach far beyond their aberrant genic product, as indicated by the genome-wide methylation changes driven by BRAF mutation in melanoma cells (Hou et al., 2011 (Hou et al., , 2012 . In the scenario of cancer predisposition, the first example of germline epimutation was the MSH2 methylation caused by deletion of the EPCAM gene in some Lynch syndrome patients (Ligtenberg et al., 2009) . Epimutation in melanoma predisposition was investigated in some melanoma-prone families negative for CDKN2A mutations, but germline hypermethylation of the CDKN2A promoter was not detected (van Doorn et al., 2009) .
Given the role of DNA methylation in tumorigenesis and the lack of epigenetic studies related to melanoma predisposition, our goal was to explore whether the presence of germline CDKN2A mutations or the occurrence of cutaneous melanoma would lead to constitutive genomewide DNA methylation changes in melanoma patients. We identified a possible constitutive epigenetic signature in CDKN2A-mutated patients, and a pattern of DNA hypomethylation in CDKN2A-negative patients relative to both CDKN2A-mutated patients and controls.
Patients and methods

Patients and control samples
This study was performed at the A. C. Camargo Cancer Center in Sao Paulo, Brazil, and the ethics committee of the institution approved the research protocol. Leukocyte DNA samples were obtained from peripheral blood, which was collected after the patients had signed informed consent forms.
Melanoma patients were referred to the Skin Cancer Department of the A. C. Camargo Cancer Center. The patients' personal and family histories of cancer were recorded. The group of hereditary melanoma patients comprised 8 unrelated probands previously found to carry pathogenic CDKN2A mutations (de Ávila et al., 2014 ; clinical data of these patients can be found in the Supplementary data 1). All CDKN2A-mutated patients were free of disease for at least one year when the peripheral blood samples were collected.
Eight leukocyte DNA samples from sporadic melanoma patients without detectable disease at the time of blood draw were also included in the study. This group of patients with sporadic melanoma was negative for CDKN2A mutations. We used eight unrelated healthy individuals as controls for the leukocyte methylome; these subjects were paired according to sex and age with the CDKN2A-mutated patients. Furthermore, additional sporadic melanoma patients (n= 46) and control individuals (n= 95) were genotyped for the SNP rs869047.
2.2. Genome-wide DNA methylation analysis 2.2.1. Infinium HumanMethylation450K BeadChips DNA methylation profiles of leukocytes were obtained using the Infinium HumanMethylation450K BeadChips (Illumina), following the manufacturer's instructions. These microarrays interrogate the DNA methylation status across 485,577 CpG loci distributed along the genome at single-nucleotide resolution. Briefly, a total of 500 ng bisulfite-converted DNA (EZ DNA methylation kit; Zymo Research) from each sample was amplified, fragmented and hybridized to BeadChips. Microarray images were captured using the iScan SQ scanner (Illumina), and only experiments exhibiting the recommended quality control parameters (call rate N0.98 of probes with detection P-value ≤ 0.01) were used. Methylation data were deposited into NCBI's Gene Expression Omnibus under the accession number GSE54939 (http://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE54939).
Differential methylation analysis
Probes lacking β-values in any sample and those mapped to chromosomes X or Y were removed from the analysis. The raw data were normalized as proposed by Touleimat and Tost (2012) , incorporating the correction of the Infinium II probe signals based on Infinium I.
To identify methylation differences among sporadic melanoma patients, CDKN2A-mutated patients and individuals without a personal history of cancer (controls), we performed statistical analysis with SAM (Significance Analysis of Microarrays, multi-class test with delta = 0.5, 100 permutations, 90th percentile FDR= 0.49%), using the β-values of the top 1% of probes with the highest standard deviation across all samples (4708 CpGs), including sporadic melanoma patients, CDKN2A-mutated patients and controls.
In addition, we performed differential methylation analysis comparing CDKN2A-mutated patients and control subjects. This analysis was carried out after obtaining the delta-β values (Δβ) for each CpG marker by subtracting the mean β-value of the CDKN2A-mutated group from the mean β-value of the control group. Next, a threshold of Δβ ≤ − 0.20 or Δβ ≥ 0.20 was applied for selecting a set of CpGs, which were submitted to the Rank Product (RP) statistical test using the MultiExperiment Viewer (MeV) software (version 4.4.1), considering 100 permutations, a two-class test and FDR at 10%.
Hierarchical clusters were constructed for both analysis (SAM and RP) for statistically significant CpG sites using Euclidean distance and average linkage.
Information about differentially methylated CpG sites was retrieved from the dataset GSE42409 available at the Gene Expression Omnibus (Price et al., 2013) , which reports SNPs and repetitive elements mapped either at CpG targets or probe sequences. In order to consider the effect of cellular heterogeneity of peripheral blood in the DNA methylation variability, differentially methylated CpG sites were matched with data provided by Jaffe and Irizarry (2014) . Ingenuity Pathway Analysis (IPA) software was used for in silico analysis of the set of differentially methylated genes. Networks were obtained using the core analysis tool, considering the Ingenuity knowledgebase (genes + endogenous chemicals), the human species, melanoma cell lines and all types of tissues and primary cells. We selected for presentation those networks with the highest scores.
Quantitative bisulfite pyrosequencing
Technical validation of the methylation level of a single CpG site (cg00631877; mapped to the PLXNC1 gene) was performed by quantitative bisulfite pyrosequencing using PyroMark Q96 ID (Qiagen). PCR was performed using the PyroMark PCR kit (Qiagen) according to the manufacturer's instructions. The following primer sequences were used:
F-[Btn]AGGAGGTTGGTGGGTTAG, R-CCACCAATTACCTCTTCC, Sequencing-TATACTCTAATATCA. After DNA bisulfite-converted amplification (input of 20-40 ng), biotinylated PCR products were precipitated using streptavidin-sepharose (GE Healthcare), and DNA strands were separated with PyroMark denaturation solution (Qiagen). Next, the samples were prepared in the PyroMark Q96 Vacuum Workstation for primer sequencing, annealed and submitted to pyrosequencing with PyroMark Gold Q96 reagents (Qiagen).
Genotyping of SNPs at CpG site
Four SNPs located at CpG sites were genotyped: cg00631877 (PLXNC1, rs869047), cg25709790 (DFNA5, rs2240005), cg13167158 (MIB2, rs11544452) and cg13078798 (TGFBR3, rs11165390). The list of primers and PCR conditions are available upon request. PCR products were sequenced using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). The capillary electrophoresis was performed in 3130xl Genetic Analyzer, following manufacturer's instructions (Applied Biosystems).
Results
SAM analysis comparing the top 1% most variable probes among sporadic melanoma patients, CDKN2A-mutated melanoma patients and controls resulted in 166 differentially methylated CpGs (Supplementary data 2). Hierarchical clustering showed that the group of sporadic melanoma patients had a distinctly hypomethylated methylome when compared to the two other groups (Fig. 1A) . Part of this set of differentially methylated sites (115 CpGs) was mapped within sequences related to 110 genes, four of which had already been linked to melanoma: NRAS, CDH5, SK1 and GRIN2A. The presence of SNPs and repetitive elements overlapping the full CpG dataset (166 CpGs) was investigated; 4.2% of the differentially methylated CpG sites were found to harbor SNPs at either cytosine or guanine, and 18.7% of the probes contained repetitive DNA in their sequences. Additionally, 130 of this set of 166 hypomethylated CpGs are sites that present methylation level varying according to the type of blood cells (see Supplementary data 2). In conclusion, this analysis showed that sporadic melanoma patients exhibit a global DNA hypomethylation profile compared to both CDKN2A-mutated patients and controls, which is mostly related to nonrepetitive sequences.
This group of 110 hypomethylated genes was then evaluated using the network analysis tool of the IPA software. The top three canonical pathways among all differentially methylated genes included Telomere Extension by Telomerase, Molecular Mechanisms of Cancer and CDK5 Signaling. The most relevant of the created networks connected 21 of these genes harboring differentially methylated CpG sites with 10 additional genes, and this network was related to Embryonic Development, Organ Development and Organismal Development (Supplementary data 3, Figure S1A ). In this network, the NRAS gene appeared to play a central role. Another network, involving 20 of the differentially methylated genes, was related to Hair and Skin Development and Function, Organ Morphology and Digestive System Development and Function (Supplementary data 3, Figure S1B ).
To identify DNA methylation differences that might be driven by the presence of germline CDKN2A mutations, the methylation status of CDKN2A-mutated patients was interrogated relative to that of the control group. We selected 589 differentially methylated CpGs (0.20 ≤ Δβ or Δβ ≤ −0.20), which were submitted to Rank Products statistical analysis. Ninety CpG sites differed significantly between groups (47 hypomethylated and 43 hypermethylated, Table 1 ), and 63 of them mapped within 58 genes or their regulatory sequences. In the hierarchical clustering analysis, only the group of hypomethylated CpGs could distinguish the CDKN2A-mutated patients from the controls (Fig. 1B) . The presence of SNPs and repetitive elements overlapping this CpG dataset was investigated, and the results indicated that 87.8% of the 90 CpG sites harbored a putative SNP at the cytosine or guanine, and 18.9% of the probes mapped fully or partially at repetitive DNA elements (Table 1) . Using one of these CpG sites, we performed a technical validation by quantitative bisulfite pyrosequencing. The obtained methylation level of the cg00631877 probe, mapped within the PLXNC1 gene, was highly correlated with 450 K microarray data (Spearman's correlation coefficient of 0.85; see Supplementary data 4). To investigate the presence of SNPs at the detected differentially methylated CpGs, we genotyped four sites in CDKN2A-mutated patients' and controls': the cg00631877, and three additional CpG sites (Table 2 ). Methylation levels measured using the 450K microarrays are directly associated with the genotype: the abolishment of CpG sites was associated to hypomethylation and, conversely, the hypermethylation was associated to the CpG site maintenance. We verify the allele frequency at rs869047 (cg00631877) in a larger group of melanoma patients (n= 62) and controls (n= 95), and no statistically significant difference was observed between groups (Fisher's exact test, P= 0.196). In summary, we found a signature distinguishing CDKN2A-mutated patients from control subjects, which was mostly related to unique sites harboring putative SNPs.
The affected set of 58 differentially methylated genes was then evaluated using IPA. Two relevant networks were generated, one of which included 14 genes from our set, and was associated with Connective Tissue Disorders, Developmental Disorders and Hereditary Disorders; in this network, the gene DYSF was connected to several other genes. The second relevant network contained 14 genes from our dataset and showed functions related to Cell-To-Cell Signaling and Interaction, Hematological System Development and Function and Immune Cell Trafficking (Fig. 2) . The top disease in this analysis was cancer, containing 26 genes from the group of detected differentially methylated genes (marked in Table 1 ). 
Discussion
This study reports the first genome-wide DNA methylation profiling of leukocytes in melanoma patients. In particular, the methylation profile of melanoma patients carrying CDKN2A mutations was analyzed relative to that of individuals without a personal history of cancer to determine whether germline mutations affecting a cancer gene could lead to epigenomic changes. Additionally, we included a group of CDKN2A-negative sporadic melanoma patients to identify DNA methylation marks possibly related to the occurrence of melanoma.
Our results showed that sporadic melanoma patients exhibited a hypomethylated profile relative to both CDKN2A-mutated patients and control subjects. The hypomethylation of this set of genes represents a possible epigenetic mark resulting from previous cancer occurrence and includes genes known to be relevant for melanoma. NRAS, an oncogene that is mutated in more than 20% of melanomas (Fedorenko et al., 2013) , was highlighted in the identified network as playing a key role, similar to the CDH5 gene, which is overexpressed in aggressive melanoma cells (Hendrix et al., 2001 ). In addition, previous studies have identified SKI as a tumor suppressor and tumor-promoting gene (Reed et al., 2005) , and GRIN2A as frequently mutated in melanoma and related to cancer progression (Prickett and Samuels, 2012; Wei et al., 2011) .
Preceding studies have investigated the DNA methylation pattern of the peripheral blood in patients with several types of cancers, in an effort to search for relevant biomarkers Langevin et al., 2012; Marsit et al., 2011; Pedersen et al., 2011; Schinke et al., 2010; Teschendorff et al., 2009; Wang et al., 2010) . Koestler and coworkers (2012) suggested that the detected methylation differences were due to changes in leukocyte subpopulations during the course of the disease. We did not detect differentially methylated CpG sites overlapping the top 50 sites proposed as a leukocyte signature of cancer patients. Therefore, melanoma patients may show a distinctive DNA methylation profile in their peripheral blood compared to other cancer patients.
In a meta-analysis study, Woo and Kim (2012) proposed that DNA hypomethylation may be a suitable biomarker for cancer risk. Accordingly, it was recently shown that this hypomethylation might be advantageous for cancer development (Friso et al., 2013) . However, CDKN2A-mutated melanoma patients did not show extensive DNA hypomethylation, suggesting that the detected difference in methylation profiles may reflect differences in the genetic etiology of the melanoma between the two groups (sporadic versus hereditary melanoma). Alternatively, it is possible that the distinct hypomethylation patterns resulted from the different time periods that elapsed from the occurrence of the cancer until the leukocytes of the melanoma patients with and without CDKN2A mutations were collected. According to Jaffe and Irizarry (2014) , the cellular composition of peripheral blood is a source of variability in DNA methylation. Thus, the occurrence of melanoma may lead to differences in the composition of blood cell populations, resulting in broad changes in the DNA methylation profile of leukocytes that would eventually decrease in frequency over time. In our study, although the group of sporadic melanoma patients was free of the disease at the time of blood draw, it still showed a hypomethylated DNA methylation profile. However, about 80% of the detected hypomethylated CpGs were sites highlighted as variable according to leukocyte cell composition (Jaffe and Irizarry, 2014) , suggesting that the detected hypomethylated profile can represent differences in cell composition as a result of the short time elapsed from the occurrence of the disease.
We also delineated a panel of CpG sites that distinguished CDKN2A-mutated melanoma patients from controls, suggesting an epigenetic signature associated with the presence of germline CDKN2A mutations. The gene SDC2 was suggested as an upstream regulator based on IPA analysis, and it is noteworthy that this gene is regulated by MC1R, a key gene involved in melanogenesis (Chung et al., 2012) . Nevertheless, the majority of sites from the panel of differentially methylated CpGs harbored putative SNPs, and this complicated the data interpretation. Because the performed methylation assay was based on the quantitative genotyping of C/T variation produced at CpG sites by bisulfite conversion, we were unable to distinguish non-methylated cytosine from thymine if there was a SNP at the interrogated CpG site. Likewise, if there was a SNP at the guanine of the dinucleotide CpG, the CpG site was lost. The 450K platform contains 4.3% of the interrogated CpG sites harboring SNPs (Price et al., 2013) , and the CpG panel that was delineated in association with germline CDKN2A mutation displayed a great enrichment of these SNP sites. This either could represent an epigenetic signature of these hereditary melanoma patients or surrogate genetic markers. To answer this question, four of these CpGs harboring SNPs sites were genotyped, all of them mapped at genes previously associated with melanoma: PLXNC1, a suppressor of melanoma progression Paliwal et al., 2013; Scott et al., 2009 ), DFNA5, a gene that contributes to resistance of melanoma to drug treatment (Lage et al., 2001 ), MIB2, reported as suppressor of melanoma invasion (Takeuchi et al., 2006) , and TGFBR3, a candidate gene to melanoma susceptibility (Walker et al., 2004) . Our data showed that the detected methylation level at these sites in melanoma patients and controls is directly associated with genetic variation. To date, seven genome-wide association studies have investigated the etiology of CDKN2A-negative familial melanoma Barrett et al., 2011; Bishop et al., 2009; Brown et al., 2008; Iles et al., 2013; Macgregor et al., 2011; Teerlink et al., 2012) , and the reported SNPs do not overlap with our gene dataset. Genetic variants can also influence the penetrance of CDKN2A mutations, such as those mapped to the repair genes POLN and PRKDC (Liang et al., 2012) , and MC1R (Fargnoli et al., 2010) . Further investigation is needed to determine whether the panel of CpGs harboring SNPs detected in CDKN2A-mutated melanoma patients influences the penetrance of the CDKN2A mutations.
In conclusion, our results demonstrate that (a) the leukocytes of sporadic melanoma patients exhibit a DNA hypomethylation pattern, possibly related to the occurrence of cancer near the time of methylome investigation, and that (b) melanoma patients carrying CDKN2A mutations display an epigenomic signature, which probably results from underlying SNPs. However, further studies in larger melanoma patient cohorts are warranted to clarify the etiology and importance of this signature.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.yexmp.2014.09.009.
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